Paraneoplastic Antibody Expanded Evaluation now available through Quest Diagnostics®

In 60% of patients with paraneoplastic neurological syndromes (PNS), the symptoms occur before the diagnosis of cancer is made.

In most cases, neurological symptoms include memory disturbance, cognitive impairment, seizures, psychosis, loss of consciousness, or even coma.

The Paraneoplastic Antibody Expanded Evaluation from Quest always uses a cell-based assay (CBA) as part of the initial panel assessment.

Detection of central nervous system autoantibodies is generally better achieved with CBAs.

65% missed by IFA alone

Utilizing CBA increases the likelihood of identifying membrane-embedded protein targets, LGI1, CASPR2, NMDA (NR1), AMPAR, and GABABR.

Reasons to test with Quest’s expanded panel:

1. Identify PNS antibodies to increase the likelihood of early diagnosis and treatment.
2. Understand disease progression and prognosis so you and your patients know what to expect.
3. Discover comorbidities or underlying conditions such as encephalitis, ataxia, or myasthenia gravis so you can plan for the appropriate care pathway.

<table>
<thead>
<tr>
<th>Test code</th>
<th>Test name</th>
<th>Turnaround time</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>94957</td>
<td>Paraneoplastic Antibody Expanded Evaluation with Reflex to Titer and LB, Serum</td>
<td>3-14 days</td>
<td>6 mL preferred (3.5 mL minimum)</td>
</tr>
<tr>
<td>94960</td>
<td>Paraneoplastic Antibody Expanded Evaluation with Reflex to Titer and LB, CSF</td>
<td>3-14 days</td>
<td>6 mL preferred (3.5 mL minimum)</td>
</tr>
</tbody>
</table>

Components of panels can be ordered separately. See chart on page 2 for component test codes.

Learn more at QuestDiagnostics.com/Neuroimmunology
The Paraneoplastic Antibody Expanded Evaluation has the ability to identify 25 prevalent antibodies, including Ma2/Ta and Zic4.

Paraneoplastic Antibody Expanded Evaluation with Reflex to Titer and Line Blot (available for Serum and CSF), consists of 3 distinct panels, with the appropriate titer reflex if an antibody is positively identified.

**Always performed**

- ANNA1 (Hu) Ab, IFA
- ANNA2 (Ri) Ab, IFA
- PCA1 (Yo) Ab, IFA
- AGNA(SOX1) Ab, IFA
- Amphiophysin Ab, IFA
- CRMP5(CV2) Ab, IFA
- GAD65 Ab, IFA
- Ma2/Ta Ab, IFA
- Aquaporin-4 Ab, IFA

**Reflex tests**

- Line blot of following analytes:
  - ANNA1 (Hu) (test code 37053)
  - ANNA2 (Ri) (test code 10140)
  - PCA1 (Yo) (test code 90119)
  - Ma2/Ta (test code 4683)
  - CV2 (CVRMPS) (test code 4681)
  - Amphiophysin (test code 4674)
  - AGNA (SOX1)
  - GAD65
  - DNER

**Tissue IFA panel**

- ANNA3 Ab, IFA
- PCA2 Ab, IFA
- PCA-Tr (DNER) Ab, IFA
- Myelin Ab, IFA (test code 4639)

**CBA panel**

- NMDAR1 Ab, CBA (test code 92394)
- AMPAR1 Ab, CBA
- AMPAR2 Ab, CBA
- GABABR Ab, CBA
- LGI-1 Ab, CBA (test code 92416)
- CASPR2 Ab, CBA (test code 92413)
- DPPX Ab, CBA (test code 93891)
- Aquaporin 4 Ab, CBA (test code 38321)

**RIA panel**

- AChR Ganglionic Ab, RIA (test code 93881)
- VGCC Type P/Q Ab, RIA (test code 34057)
- VGCC Type N Ab, RIA (test code 93882)
- VGKC Ab, RIA (test code 93883)


Test codes may vary by location. Please contact your local laboratory for more information.

Image content features models and is intended for illustrative purposes only.